Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase I/IIa Randomized Clinical Trial to Evaluate the Efficacy of EGFR-targeted, PNU-159682-packaged Nanocells & Glycolipid-Packaged Nanocells in Combination With Gemcitabine & Nab-paclitaxel in Metastatic Pancreatic Ductal Adenocarcinoma

NCT07049055 is registered in ClinicalTrials.gov with Engeneic Pty Limited as lead sponsor.

NCT NCT07049055
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07049055 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase I/IIa Randomized Clinical Trial to Evaluate the Efficacy of EGFR-targeted, PNU-159682-packaged Nanocells & Glycolipid-Packaged Nanocells in Combination With Gemcitabine & Nab-paclitaxel in Metastatic Pancreatic Ductal Adenocarcinoma
Lead sponsor
Engeneic Pty Limited
Phase
Phase 1/2
Overall status
Recruiting
Start date
January 12, 2026
Completion date
September 30, 2028
Enrollment
144 (estimated)
Sites
4

Conditions

As the registry lists them; a condition with its own page is linked.

pancreatic cancer, metastatic, pdac - pancreatic ductal adenocarcinoma